IV Therapy Use and Compatibility Chart © Paul S. Anderson 2015 - Prepared For Anderson Medical Group, BCRC and SCRI - All Rights Reserved

IV Therapy Use and Compatibility Chart
© Paul S. Anderson 2015 – Prepared for Anderson Medical Group, BCRC* and SCRI* – All rights reserved
Item # Therapy / Agent Potential MOA Compatibility Notes

1 Ascorbate – Low dose Antioxidant, VEGF inhibitor, QOL, Chemo/Rad sensitizer, 4,5,6,7,8,9,10,-19 a, e
2 Ascorbate – High dose Oxidant – ROS Burst, VEGF inhibitor, Chemo/Rad sensitizer, 3,4,5,6,18,19 b
3 Artesunate Oxidant - ROS Burst, Immune modulator (opposes autoimmune TH imbalance) 2,4,5, 19 c, d, e, g
4 DCA Alkylating agent, Metabolism switching – aerobic facilitator, ROS generator 1,2,3,5-18 d
5 Vitamin K Oxidant [K3], Growth and Cell Cycle arrest [K1,2] 1-19 [depending on form] e
6 Germanium Natural Killer Cell function enhancer, TNFg inducer, T-cell inducer, SOD enhancer 1-19 d, f
7 Transition metals Cofactor support 1, 4-19 e, f
8 B-Vitamins Cofactor support 1, 4-19 e, f
9 Glutathione GSH donor, QOL, Chemo sensitization 1, 4-19 d, e
10 ALA GSH support, antioxidant, QOL, GLUT-receptor stimulator, NF(k)B stabilizer, Tumor cell anti- 1, 4-19 d, e
proliferation / Apoptotic agent
11 LAMC [Poly-MVA] GSH / mitochondrial support, Metabolism switching – aerobic facilitator, Apoptotic agent, HIF-1 1, 4-19 d, e
inhibitor, QOL
12 Curcumin Antioxidant, Immune modulator, NF(k)B inhibitor, affects growth factor receptors and cell adhesion 1, 4-19 d
molecules involved in tumor growth, angiogenesis and metastasis
13 Resveratrol Chemo sensitizer, Affects - cell growth, inflammation, apoptosis, angiogenesis, and invasion and 1, 4-19 d
metastasis. Potential as antioxidant and pro-oxidant.
14 Silibinin Hepatic GSH support, Chemo sensitizer, Prevention of chemotherapy induced toxicity, 1, 4-19 d
immunomodulator, QOL
15 Quercetin Antioxidant, antiproliferative and antimutagenic, apoptosis inducer 1, 4-19 d
16 Calcitriol Taxane and Platin enhancer, Apoptotic agent, Antiproliferant, Hedgehog signal inhibitor, cell cycle 1, 4-19 d
arrest, differentiation, angiogenesis and inhibition of cell invasiveness
17 EGCG Chemo preventive, Inhibition of heat shock proteins, Ascorbate synergist (potential) 1, [2?], 4-19 d
18 Phospholipids Lipid exchange, Membrane stabilizer, Acetylcholine primer, etc. 1-20 d, g
19 Silver Hydrosol Disruptor of: Infectious agents & biofilms. Potential oncologic uses 1-3; 5-18 d, g
20 H2O2, Ozone Cytokine stimulant (via ReDox + Enzymatic activity in plasma) PMID: 19260079, 20335512 *h 
21 UV Blood Irradiation Multiple MOA - PMID: 6182067, 2631372, 2389276 *i
Notes: a – ‘Low’ dose is considered under 15-20 grams h – Based on MOA, pure oxidative enzymatic agents such as H2O2 + O3 should
be allowed to work on their own for a period of time. The downstream enzymatic cytokine
b – ‘High’ dose is over 15-20 grams but may reach 100-200 grams cascade from these therapies can proceed for hours following administration. In protecting
this cascade and maximizing its effectiveness the recommendation is to have no other IV
c – Generally given directly prior to other oxidant IV’s therapy for 4-6 hours after these IV’s.
d – Compatible in the same time period; not in the same IV bag i – MOA are complicated and not fully elucidated. Based on the available data it
would be reasonable to consider that UVBI could be used in series with most other
e – Compatibility depends on form of vitamin K
therapies. Some data [PMID: 20335512] show that O3 + UV (and possibly O3 alone) do
f – Compatible with water soluble IV formulas speed ascorbate oxidation – so a theoretical benefit may exist in coupling oxidant ascorbate
therapy and UV or UV+O3.
g – Based on multiple MOA may be used in both ReDox environments
All information provided is based on literature review as of 08-2015 and every attempt to ensure accuracy has been made. This information is subject to change as data emerge. The clinician should exert
final judgment prior to implementing any therapy mentioned in this summary. References for all mechanistic statements are contained in the IV Therapy notes presented separately. BCRC – Bastyr Clinical
Research Center; SCRI – Southwest College Research Institute.

IV Therapy Use and Compatibility Chart © Paul S. Anderson 2015 - Prepared For Anderson Medical Group, BCRC and SCRI - All Rights Reserved

Uploaded by

Copyright:

Available Formats

IV Therapy Use and Compatibility Chart © Paul S. Anderson 2015 - Prepared For Anderson Medical Group, BCRC and SCRI - All Rights Reserved

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

IV Therapy Use and Compatibility Chart © Paul S. Anderson 2015 - Prepared For Anderson Medical Group, BCRC and SCRI - All Rights Reserved

Uploaded by

Copyright:

Available Formats

IV Therapy Use and Compatibility Chart

Item # Therapy / Agent Potential MOA Compatibility Notes

You might also like